Introduction Xijing Hospital, a general medical hospital, is located in Xi'an, China and is affiliated with the Fourth Military Medical University. |
Disease Domain | Count |
---|---|
Neoplasms | 1 |
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
CAR-T | 1 |
Top 5 Target | Count |
---|---|
HMGB1 x NLRP3 x TLR4 | 1 |
MG7 | 1 |
Target |
Mechanism MG7 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HMGB1 inhibitors [+2] |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism VDCCs blockers |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator Xijing Hospital [+2] |
Start Date15 May 2025 |
Sponsor / Collaborator Xijing Hospital [+1] |
Start Date20 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Anti-MG7 CAR T cell therapy(Shanghai Genechem Co., Ltd.) ( MG7 ) | Liver Cancer More | Phase 2 |
Acteoside ( HMGB1 x NLRP3 x TLR4 ) | Ischemic stroke More | Preclinical |
Ginsenoside Rd ( VDCCs ) | Stroke More | Discontinued |
68Ga-HER2 Affibody | HER2-positive gastric cancer More | Pending |
68Ga-Sgc8 ( PTK7 ) | Colorectal Cancer More | Pending |